{
  "id": 4708104,
  "title": "Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.",
  "url": "https://urgent.news/2026/08/31/teva-and-trump-administration-announce-intent-to-reach-agreement",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-31T20:10:47.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/teva-and-trump-administration-announce-intent-to-reach-agreement-around-affordable-medicines-and-supply-chain-security-for-patients-in-the-u-s"
  },
  "original_language": "en",
  "account": "On August 31, 2026, Teva Pharmaceuticals and the Trump Administration announced their intention to reach an agreement aimed at reducing the cost of certain medicines for Medicaid patients in the United States. This partnership seeks to encourage continued investment in medical research and manufacturing in the U.S.\n\nTeva USA's President, Chris Fox, expressed the company's appreciation for the opportunity to collaborate with President Trump and his Administration. The goal of this collaboration is to improve patient access to affordable medications while simultaneously fostering continued investment in the pharmaceutical industry. Teva has been committed to delivering cost-effective medicines to American patients, and it shares the Administration's dedication to making these medicines more accessible and affordable.\n\nThe proposed agreement would align U.S. Medicaid pricing with that of leading developed countries under the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) framework. This would result in lower drug prices for patients covered by Medicaid. Moreover, the agreement would entail a Most-Favored-Nation (MFN) commitment for upcoming innovative product launches, ensuring continued competitive pricing.\n\nIn addition to the pricing aspects, Teva has pledged to maintain a reserve of specific active pharmaceutical ingredients (APIs) for public health purposes. This commitment also encompasses ongoing investment into U.S. pharmaceutical manufacturing capabilities. However, the conditions of these negotiations remain confidential for now.",
  "summary": "PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced a shared commitment with the Trump Administration to lower the cost of select medicines for American patients covered by Medicaid. When finalized, this agreement will support continued […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Guardian Health",
        "title": "Trump EPA is manipulating safety data around a highly toxic flame retardant, advocates allege",
        "url": "https://urgent.news/2026/08/30/trump-epa-is-manipulating-safety-data-around-a-highly-toxic-flame",
        "published": "2026-08-30T13:00:56.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}